Alternate site health provider Option Care Health (NASDAQ: OPCH) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 1.9% year on year to $1.44 billion. The company expects the full year’s revenue to be around $5.73 billion, close to analysts’ estimates. Its non-GAAP profit of $0.45 per share was 5.4% above analysts’ consensus estimates.

Is now the time to buy Option Care Health? Find out by accessing our full research report, it’s free.

John C. Rademacher, Chief Executive Officer, commented, “I’m proud of our team as we delivered strong second quarter results, reflecting solid operational execution and the positive impact of our 2026 strategic initiatives. Looking ahead, our results reinforce our confidence in the underlying fundamentals of the business, but there is still work to do as we further position the company for a sustainable long-term growth trajectory. Given the strength of our clinical platform, significant market opportunities and our operational focus, we believe we are well positioned to achieve our 2026 priorities while creating meaningful value for our patients, partners, and shareholders.”

Company Overview

With a nationwide network of 177 locations serving 43 states and a team of over 4,500 clinicians, Option Care Health (NASDAQ: OPCH) is the largest independent provider of home and alternate site infusion services, delivering medications and clinical support to patients across the United States.

Revenue Growth

Reviewing a company’s long-term sales performance reveals insights into its quality. Any business can have short-term success, but a top-tier one grows for years. Over the last five years, Option Care Health grew its sales at a solid 12.2% compounded annual growth rate. Its growth beat the average healthcare company and shows its offerings resonate with customers.

Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Option Care Health’s annualized revenue growth of 11.4% over the last two years aligns with its five-year trend, suggesting its demand was stable.

This quarter, Option Care Health reported modest year-on-year revenue growth of 1.9% but beat Wall Street’s estimates by 1.6%.

Looking ahead, sell-side analysts expect revenue to grow 3.8% over the next 12 months, a deceleration versus the last two years. This projection doesn’t excite us and indicates its products and services will face some demand challenges.

ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.

AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.

Adjusted Operating Margin

Adjusted operating margin is one of the best measures of profitability because it tells us how much money a company takes home after subtracting all core expenses, like marketing and R&D. It also removes various one-time costs to paint a better picture of normalized profits.

Option Care Health’s adjusted operating margin has more or less stayed the same over the last 12 months , averaging 7.3% over the last five years. This profitability was mediocre for a healthcare business and caused by its suboptimal cost structure.

Looking at the trend in its profitability, Option Care Health’s adjusted operating margin might have fluctuated slightly but has generally stayed the same over the last five years. This raises questions about the company’s expense base because its revenue growth should have given it leverage on its fixed costs, resulting in better economies of scale and profitability.

This quarter, Option Care Health generated an adjusted operating margin profit margin of 6.5%, in line with the same quarter last year. This indicates the company’s overall cost structure has been relatively stable.

Earnings Per Share

Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth — for example, a company could inflate its sales through excessive spending on advertising and promotions.

Option Care Health’s EPS grew at 29.4% compounded annual growth rate over the last five years, higher than its 12.2% annualized revenue growth. However, this alone doesn’t tell us much about its business quality because its adjusted operating margin didn’t improve.

We can take a deeper look into Option Care Health’s earnings quality to better understand the drivers of its performance. A five-year view shows that Option Care Health has repurchased its stock, shrinking its share count by 15.2%. This tells us its EPS outperformed its revenue not because of increased operational efficiency but financial engineering, as buybacks boost per share earnings.

In Q2, Option Care Health reported adjusted EPS of $0.45, up from $0.41 in the same quarter last year. This print beat analysts’ estimates by 5.4%. Over the next 12 months, Wall Street expects Option Care Health’s full-year EPS to grow 9.5% from $1.76 to $1.93.

Key Takeaways from Option Care Health’s Q2 Results

We enjoyed seeing Option Care Health beat analysts’ full-year EPS guidance expectations this quarter. We were also happy its revenue outperformed Wall Street’s estimates. Overall, this print had some key positives. The stock traded up 6.5% to $23.95 immediately after reporting.

Option Care Health had an encouraging quarter, but one earnings result doesn’t necessarily make the stock a buy. Let’s see if this is a good investment. We think that the latest quarter is only one piece of the longer-term business quality puzzle. Quality, when combined with valuation, can help determine if the stock is a buy. We cover that in our actionable full research report which you can read here (it’s free).